AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results For ABCL635, Demonstrating Significant Reduction In Frequency And Severity Of Vasomotor Symptoms And A Favorable Tolerability Profile
ABCL•Phase 2 results for ABCL635
Aug. 10 (Reuters) - AbCellera Biologics Inc. (ABCL.O):
- AbCellera announces positive top-line Phase 2 clinical trial results for ABCL635, demonstrating significant reduction in frequency and severity of vasomotor symptoms and a favorable tolerability profile.
- Phase 2 results show best-in-class reductions in vasomotor symptoms after single dose.
- ABCL635 significantly improves sleep and patient global impression of change.
- ABCL635 demonstrates favorable tolerability profile.
- Study meets primary efficacy endpoints with significant reductions at week 4.
- ABCL635 well-tolerated with no serious or severe adverse events.
